contact | site map
Lab21 Ltd to Provide AdnaGen’s System for CTCs in the United Kingdom and Ireland      OVIT Announces Collaboration with MDACC on AdnaGen CTC Assay Development      AndaGen AG Completes Successful Financial Restructuring       --= NFSP =--      CTRC and OncoVista Announce Initiation of Collaboration on Clinical Development of OVI-117      
  • latest news
  • who are we?
  • what makes
    us different?
  • what is our
    product pipeline?
  • what is our drug
    development strategy?
  • investor
    relations
corporate profile & landmarks | management team | clinical advisory board | operations strategy | capabilities & affiliations | our location
cancer facts | current cancer chemotherapy | our keys to success
AdnaGen diagnostics | OVI-237 | OVI-123 | OVI-117 | tubulin isotype-specfic anti-mitotics
use of CTCs in cancer drug development | our unique approach
press releases | our strategy for creating value | SEC Filings | stock quote | corporate presentation | IP summary | corporate governance | company contact and investor relations | S&P Market Access Profile

Corporate Governance

 

Our Code of Business Conduct and Ethics

Audit Committee Charter

Compensation Committee Charter 

Our Board of Directors

Our Practices

Complaints
 


home | site map | contact us | terms of use